Vor Bio appoints Han Choi as CFO, effective Sept 30, 2024

Vor Biopharma Inc.

Han Choi, M.D., LL.M., named CFO; previously Principal at Oracle Investment Management for over 20 years.
Base salary of $464,000 per year and target annual bonus of 40% of base salary.
Granted stock option for 400,000 shares, vesting over 4 years (1/4 after 1 year, then monthly).
Choi brings experience in healthcare investment, business development, and capital markets strategy.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Han Choi

Chief Financial Officer

VOR · Vor Biopharma Inc.

Effective: 2024-09-30
Filed: September 30, 2024, 7:59 PM ET

On September 30, 2024, Vor Biopharma Inc. (the “Company”) announced that the board of directors (the “Board”) has appointed Han Choi, M.D., LL.M., as Chief Financial Officer of the Company, effective as of September 30, 2024 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Han Choi was appointed as Chief Financial Officer at Vor Biopharma Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On September 30, 2024, Vor Biopharma Inc. (the “Company”) announced that the board of directors (the “Board”) has appointed Han Choi, M.D., LL.M., as Chief Financial Officer of the Company, effective as of September 30, 2024 (the “Effective Date”).

View on SEC.gov

Vor Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-228399

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.